<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Given the potential for recovery in recent <z:hpo ids='HP_0003674'>onset</z:hpo> nonischemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (ROCM), the timing and need for implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>) remains controversial </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the utilization of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e> and the impact on survival for subjects with ROCM </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: An National Heart, Lung, and Blood Institute sponsored registry enrolled 373 subjects with ROCM, <z:hpo ids='HP_0000001'>all</z:hpo> with a left ventricular ejection fraction (LVEF) ≤0.40 and ≤6 months of symptoms </plain></SENT>
<SENT sid="3" pm="."><plain>The mean age was 45 ± 14 years, 38% were female, 21% black, 75% New York Heart Association II/III, and the mean LVEF was 0.24 ± 0.08 </plain></SENT>
<SENT sid="4" pm="."><plain>Survival was comparable for subjects with an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> within 1 month of entry (n = 43, 1/2/3 year % survival = 97/97/92) and those with no <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> at 1 month (n = 330, % survival = 98/97/95, P = .30) and between those with and without an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> at 6 months (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>, n = 73, 1/2/3 year % survival = 98/98/95; no <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>, n = 300, % survival = 98/96/95, P = .95) </plain></SENT>
<SENT sid="5" pm="."><plain>There were only 6 <z:hpo ids='HP_0001645'>sudden cardiac deaths</z:hpo> (SCD) noted (% survival free from SCD = 99/98/97) and these occurred in 1.9% of subjects without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> and 0.9% of those with a device (P = .50) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: In a multicenter cohort of ROCM the risk of SCD was low at 1% per year </plain></SENT>
<SENT sid="7" pm="."><plain>Early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> placement did not impact survival and can be deferred while assessing potential for myocardial recovery </plain></SENT>
</text></document>